Predictive and Presymptomatic Testing Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 8.40 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Predictive and Presymptomatic Testing Market Analysis
The predictive and presymptomatic testing market is poised to grow at a CAGR of 8.4% over the forecast period.
The emergence of COVID-19 had its impact on the predictive and presymptomatic testing market as during the initial pandemic days there were strict lockdown restrictions imposed by the governments to curb the spread of COVID-19 which led to a decline in the number of predictive and presymptomatic testing. However, the market is recovering since the lockdown restrictions were lifted around the world and as the cases of COVID-19 are on the decline and the demand for predictive and presymptomatic tests is increasing. Hence, the studied market is expected to grow over the forecast period.
The market for predictive and presymptomatic testing is expected to grow over the forecast period due to factors such as the increasing prevalence of genetic disorders and rising demand for genetic counseling as they can be used to determine whether the patient has a hereditary disease-causing mutation or genetic disorders. Also, the rising awareness regarding genetic diseases among the global population is leading to an increase in demand for genetic counseling, thereby contributing to the growth of the market. For instance, the NHP data published in June 2021 stated that 300 million people are living with a rare disease worldwide and 70% that genetic rare diseases start in childhood. Similarly, according to the article published by Frontiers in 2021, in Japan, the rare hereditary disease prevalence was equivalent to less than 1 in 2,500 people. Also, as per the PHO statistics in 2021, about 10,000 diseases are monogenetic worldwide. Such a high prevalence of rare hereditary diseases and genetic disorders is expected to contribute to the demand for predictive and presymptomatic testing, thereby boosting the market growth.
Furthermore, the launch of new predictive and presymptomatic testing services across the globe, increasing investments, rising research and development activities, and adoption of key strategic initiatives by key market players are expected to contribute to the significant growth of the market. For instance, in September 2021, MedGenomeLabs launched its direct-to-consumer website, Genessense for consumers in India. The company offered two tests, Kardiogen and Curegen, through the Genessense website e-commerce platforms. Kardiogenis a polygenic risk score-based predictive test for coronary artery disease with a proven specificity of 90% for the Indian population. Thus, the above-mentioned factors are expected to drive the growth of the market during the forecast period. However, the high costs of tests and ethical issues in predictive testing are expected to restrain the development of the market.
Predictive and Presymptomatic Testing Market Trends
This section covers the major market trends shaping the Predictive & Presymptomatic Testing Market according to our research experts:
Breast and Ovarian Cancer is Expected to Witness Highest CAGR Over the Forecast Period
The breast and ovarian cancer segment is expected to dominate the market due to the high prevalence of genetically inherited cancer among the global population and the rising demand for early diagnosis.
The growth of the studied segment is mainly due to the identification of the BRCA1 and BRCA2 genes responsible for hereditary breast/ovarian cancer (HBOC) for the prevention of genetically inherited cancer. As per the NCBI study published in February 2021, early detection has the potential to reduce cancer mortality, but an effective screening test must demonstrate asymptomatic cancer detection years before conventional diagnosis. The study stated that late-stage cancers often lack an effective treatment option. Survival rates increase significantly when cancer is identified at early stages, as the tumor can be surgically removed or treated with milder drug regimens. Thus, such research studies proving the importance of early screening for the detection of breast and ovarian cancers to obtain appropriate treatments are also expected to contribute to the growth of the studied segment.
On the other hand, frequent product launches to meet the growing demand for presymptomatic testing of breast cancer and ovarian cancer are also expected to contribute to the growth of the studied segment. For instance, in March 2022, LifeCell launched a breast screen panel, a comprehensive genetic screening test that assesses the risk of breast cancer in women. The panel not only screens for the mutations in the most common BRCA1 and BRCA2 genes but also screens for all 20 high and moderate-risk non-BRCA genes associated with hereditary breast and ovarian cancer.
The increasing prevalence of genetically inherited breast and ovarian cancer, globally, is a major driver for the use of predictive and presymptomatic tests for these cancers, as a conventional cancer treatment is non-effective in such cases and a pre-emptive mastectomy is the only available treatment for BRCA-mediated breast and ovarian cancer. For instance, as per the ACS data published in June 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States along with 51,400 non-invasive breast cancer in 2022. Such prevalence of breast cancer among the population is expected to contribute to the growth of the studied segment.
North America is Expected to Hold Significant Share in the Market the Predictive and Presymptomatic Testing Market Over the Forecast Period
North America is expected to hold a significant share of the market over the forecast period due to increasing awareness about genetic counseling, the rising prevalence of genetic disorders, high adaptability to advanced diagnostics, and a well-structured healthcare system. For instance, according to the United States Oncology Network data published in August 2021, more than 21,500 patients received genetic consultations at 14 Genetic Risk Evaluation and Testing (GREAT) practices in the United States Oncology Network with an 8% mutation identification rate. Such a high preference for genetic counseling to be aware of genetically inherited diseases is expected to contribute to the growth of the market.
Also, the increasing prevalence of various cancer cases in North American countries is expected to contribute to the growth of the market. For instance, as per the American Cancer Society data in 2022, it is estimated that around 65,950 new cases of uterine body cancer are diagnosed in the United States, in 2022. Also, an NCBI article published in May 2022, mentioned that an estimated 233,900 cancer are expected in Canada in 2022. Such an increase in cancer cases in this region is expected to drive the demand for predictive and presymptomatic testing, thereby contributing to the growth of the market in North America.
Additionally, with high investment related to the diagnosis and management of the United States genetic disorders by the government and private entities, the market is expected to grow in the United States over the forecast period. For instance, the Lancet Journal article published in November 2022, mentioned that in March 2022, a USD 289 million increase in research funding to the NIH for Alzheimer's disease and related dementias was signed into law, bringing total funding for these diseases by the NIH to more than USD 3 billion. Therefore, due to these above-mentioned factors, such as the high prevalence of genetically inherited diseases, increasing awareness among the population and high investment by the government, the predictive and presymptomatic testing market is expected to grow during the forecast period in the region.
Predictive and Presymptomatic Testing Industry Overview
The predictive and presymptomatic testing market is moderately competitive and is majorly comprised of local players in different countries. Some of the global players such as 23andMe, Abbott Laboratories, and Myriad Genetics hold a major share of the market. With the growing focus on genetic testing, it is expected that a few small to mid-sized companies will penetrate the market in the near future.
Predictive and Presymptomatic Testing Market Leaders
-
23andMe
-
Abbott Laboratories
-
Quest Diagnostics Inc.
-
Myriad Genetics
-
Positive Bioscience
*Disclaimer: Major Players sorted in no particular order
Predictive and Presymptomatic Testing Market News
- In July 2022, GeneType partnered with Melbourne-based Siles Health to implement geneType Multi-risk test as part of their commitment to remain at the forefront of contemporary personalized patient health care.
- In March 2022, NalageneticsPte. Ltd. received USD 12.6 million in a Series A round of financing. With the investment, the company is planning to expand its genetic testing solutions to implement predictive and presymptomatic testing for prevention geared toward chronic conditions in Asia.
Predictive and Presymptomatic Testing Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Genetic Disorders
4.2.2 Increasing Demand for Genetic Counselling
4.3 Market Restraints
4.3.1 High Cost of Tests
4.3.2 Ethical Issues in Predictive Testing
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Condition
5.1.1 Breast and Ovarian Cancer
5.1.2 Colorectal Cancer
5.1.3 Alzheimer's Disease
5.1.4 Multiple Endocrine Neoplasia Type 2
5.1.5 Haemochromatosis
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 23andMe
6.1.2 Abbott Laboratories Inc.
6.1.3 Quest Diagnostics Inc.
6.1.4 Positive Bioscience
6.1.5 Color Genomics
6.1.6 Gene by Gene
6.1.7 Mapmygenome
6.1.8 Myriad Genetics
6.1.9 BioAxis DNA Research Center Private Limited
6.1.10 Direct Laboratory Services LLC
6.1.11 Pathway Genomics Corporation
6.1.12 Ambry Genetics Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Predictive and Presymptomatic Testing Industry Segmentation
As per the scope of the report, the predictive and presymptomatic test is a type of genetic test, which is used for the detection of gene mutations for disorders that appear in later stages of life. Predictive and presymptomatic testing finds immense potential among people, who have a family member with a genetic disorder. This test is particularly effective when no features of the disorder are visible at the time of testing. The Predictive and Presymptomatic Testing market is Segmented by Condition (Breast and Ovarian Cancer, Colorectal Cancer, Alzheimer's Disease, Multiple Endocrine Neoplasia Type - 2, and Haemochromatosis), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Condition | |
| Breast and Ovarian Cancer | |
| Colorectal Cancer | |
| Alzheimer's Disease | |
| Multiple Endocrine Neoplasia Type 2 | |
| Haemochromatosis |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Predictive and Presymptomatic Testing Market Research FAQs
What is the current Predictive and Presymptomatic Testing Market size?
The Predictive and Presymptomatic Testing Market is projected to register a CAGR of 8.40% during the forecast period (2024-2029)
Who are the key players in Predictive and Presymptomatic Testing Market?
23andMe, Abbott Laboratories, Quest Diagnostics Inc., Myriad Genetics and Positive Bioscience are the major companies operating in the Predictive and Presymptomatic Testing Market.
Which is the fastest growing region in Predictive and Presymptomatic Testing Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Predictive and Presymptomatic Testing Market?
In 2024, the North America accounts for the largest market share in Predictive and Presymptomatic Testing Market.
What years does this Predictive and Presymptomatic Testing Market cover?
The report covers the Predictive and Presymptomatic Testing Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Predictive and Presymptomatic Testing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Property and Casualty Insurance in Netherlands Industry Report
Statistics for the 2024 Property and Casualty Insurance in Netherlands market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Property and Casualty Insurance in Netherlands analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
